Circulation, 146, 657-672 Circulation : an official journal of the American Heart Association / ed.-in-chief Ephraim Donosco 146(9), 657-672 (2022). doi:10.1161/CIRCULATIONAHA.121.057807 Hagström, E, Steg, P G, Szarek, M, Bhatt, D L, Bittner, V A, Danchin, N, Diaz, R, Goodman, S G, Harrington, R A, Jukema, J W, Liberopoulos, E, Marx, N, McGinniss, J, Manvelian, G, Pordy, R, Scemama, M, White, H D, Zeiher, A M, Schwartz, G G, ODYSSEY OUTCOMES Investigators & Bøttcher, M 2022, ' Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab ', Circulation, vol. 146, no. 9, pp. 657-672 . https://doi.org/10.1161/CIRCULATIONAHA.121.057807 Circulation, vol 146, iss 9 Circulation, 146, 9, pp. 657-672 Circulation, Philadelphia : Lippincott Williams & Wilkins, 2022, vol. 146, iss. 9, p. 657-672 Circulation, 146(9), 657-672. LIPPINCOTT WILLIAMS & WILKINS
Journal of the American College of Cardiology, 78(5), 421-433. ELSEVIER SCIENCE INC Journal of The American College of Cardiology, New York : Elsevier Biomedical, 2021, vol. 78, no. 5, p. 421-433 Repositorio Universidad de Santander Universidad de Santander instacron:Universidad de Santander Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Gabriel Steg, P, Gabriel Steg, P H, Bhatt, D L, Harrington, R A, Zeiher, A M, Tricoci, P, Roe, M T, Mahaffey, K W, Edelberg, J M, Hanotin, C, Lecorps, G, Moryusef, A, Sasiela, W J, Tamby, J F, Aylward, P E, Drexel, H, Sinnaeve, P, Dilic, M, Lopes, R D, Gotcheva, N N, Prieto, J C, Yong, H, Pećin, I, Reiner, Z, Clemmensen, P, Bang, L E, Hove, J D, Gislason, G, Larsen, J, Johansen, P, Jeppesen, J, Nielsen, P K, Hansen, O, Jensen, S A, Rosenberg, M, Andersen, D & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Schwartz, G G, Szarek, M, Bittner, V A, Diaz, R, Goodman, S G, Jukema, J W, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R, Scemama, M, Sinnaeve, P, White, H D, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2021, ' Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol ', Journal of the American College of Cardiology, vol. 78, no. 5, pp. 421-433 . https://doi.org/10.1016/j.jacc.2021.04.102 Journal of the American College of Cardiology, vol 78, iss 5